$0.5800
0.047.41%
In chiusura: -
$0.5851
0.005100.88%
After hour: Aug 15, 7:49 PM EDT
Sangamo Therapeutics segnala gli utili su base trimestrale. Questi report sugli utili trimestrali offrono agli investitori uno sguardo ai risultati finanziari di un'azienda per un periodo di 3 mesi. I report sugli utili includono quasi sempre i risultati EPS e i ricavi.
Analizza lo storico degli utili di Sangamo Therapeutics utilizzando ordinamenti e filtri avanzati.
Get Alert | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
SGMO | Sangamo Therapeutics | $0.04 | -$0.11 | — | — | $49.41M | $6.40M | — | — | 11/11/2025 | |
SGMO | Sangamo Therapeutics | -$0.18 | -$0.13 | -$0.08 | 20.00% | $356.00K | $31.68M | $18.31M | -32.42% | 08/07/2025 | |
SGMO | Sangamo Therapeutics | -$0.27 | -$0.13 | -$0.14 | -7.69% | $481.00K | $7.42M | $6.44M | -13.25% | 05/12/2025 | |
SGMO | Sangamo Therapeutics | -$0.34 | -$0.09 | -$0.11 | -22.22% | $2.04M | $13.62M | $7.55M | -52.51% | 03/17/2025 | |
SGMO | Sangamo Therapeutics | -$0.59 | -$0.03 | $0.04 | 233.33% | $9.40M | $17.94M | $49.41M | 175.43% | 11/12/2024 | |
SGMO | Sangamo Therapeutics | -$0.37 | -$0.15 | -$0.18 | -20.00% | $6.83M | $8.26M | $356.00K | -95.69% | 08/06/2024 | |
SGMO | Sangamo Therapeutics | $0.12 | -$0.21 | -$0.27 | -28.57% | $157.96M | $6.65M | $481.00K | -92.77% | 05/09/2024 | |
SGMO | Sangamo Therapeutics | -$0.32 | -$0.26 | -$0.34 | -30.77% | $27.23M | $8.10M | $2.04M | -74.79% | 03/13/2024 | |
SGMO | Sangamo Therapeutics | -$0.34 | -$0.32 | -$0.59 | -84.38% | $26.46M | $10.40M | $9.40M | -9.63% | 11/01/2023 | |
SGMO | Sangamo Therapeutics | -$0.29 | -$0.34 | -$0.37 | -8.82% | $29.38M | $14.83M | $6.83M | -53.91% | 08/08/2023 | |
SGMO | Sangamo Therapeutics | -$0.30 | -$0.33 | $0.12 | 136.36% | $28.23M | $24.06M | $157.96M | 556.51% | 04/26/2023 | |
SGMO | Sangamo Therapeutics | -$0.26 | -$0.10 | -$0.32 | 11.11% | $27.99M | $12.75M | $27.23M | 1.38% | 02/22/2023 | |
SGMO | Sangamo Therapeutics | -$0.33 | -$0.10 | -$0.34 | 2.86% | $28.56M | $12.75M | $26.46M | -0.49% | 11/03/2022 | |
SGMO | Sangamo Therapeutics | -$0.33 | $0.20 | -$0.29 | 17.14% | $27.87M | $12.25M | $29.38M | 19.28% | 08/04/2022 | |
SGMO | Sangamo Therapeutics | -$0.32 | -$0.09 | -$0.30 | 3.23% | $26.28M | $10.37M | $28.23M | 3.45% | 05/05/2022 | |
SGMO | Sangamo Therapeutics | -$0.29 | -$0.34 | -$0.26 | 23.53% | $25.80M | $26.82M | $27.99M | 4.35% | 02/24/2022 | |
SGMO | Sangamo Therapeutics | -$0.01 | -$0.34 | -$0.33 | 2.94% | $57.76M | $25.19M | $28.56M | 13.39% | 11/04/2021 | |
SGMO | Sangamo Therapeutics | -$0.26 | -$0.31 | -$0.33 | -6.45% | $21.55M | $26.48M | $27.87M | 5.26% | 08/05/2021 | |
SGMO | Sangamo Therapeutics | -$0.37 | -$0.30 | -$0.32 | -6.67% | $13.08M | $23.98M | $26.28M | 9.59% | 05/04/2021 | |
SGMO | Sangamo Therapeutics | $0.04 | -$0.21 | -$0.29 | -38.10% | $54.85M | $32.15M | $25.80M | -19.75% | 02/24/2021 | |
SGMO | Sangamo Therapeutics | -$0.24 | — | -$0.01 | — | $21.96M | — | $57.76M | — | 11/04/2020 |
Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
---|---|---|---|---|
Q2 | 2025-08-07 | $-0.08 | $-0.13 | 20.0 % |
Q1 | 2025-05-12 | $-0.14 | $-0.13 | -7.69 % |
Q4 | 2025-03-17 | $-0.11 | $-0.09 | -22.2 % |
Q3 | 2024-11-12 | $0.04 | $-0.03 | 233.3 % |
Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
---|---|---|---|---|
Q2 | 2025-08-07 | $18.31M | $31.68M | -32.4 % |
Q1 | 2025-05-12 | $6.44M | $7.42M | -13.3 % |
Q4 | 2025-03-17 | $7.55M | $13.62M | -52.5 % |
Q3 | 2024-11-12 | $49.41M | $17.94M | 175.4 % |
Si prevede che Sangamo Therapeutics (SGMO) fornisca risultati il novembre 11, 2025. Gli ultimi risultati sono stati pubblicati il agosto 7, 2025 per il Q2.
L'EPS effettivo era $-0.08, che superato la stima di $-0.13.
Le entrate effettive sono state $18.3M, che mancato la stima di $31.7M.
Sfoglia stime sugli utili, EPS e ricavi su tutte le azioni.